RJA
AMGN icon

Raymond James & Associates’s Amgen AMGN Stock Holding History

Raymond James & Associates’s Portfolio AMGN Stock Details AMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,300
Closed -$1.27M – 3993
2024
Q2 		$1.27M Buy
+4,300
New +$1.26M ﹤0.01% 2465

Other funds holding AMGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Raymond James & Associates's AMGN Position: Q3 2024 in Review

Raymond James & Associates reduced its Amgen (AMGN) stake by 7.1% in Q3 2024, selling an estimated $24.7M and leaving 989,504 shares worth $319M. The position accounts for 0.19% of the portfolio, ranked #95.

Raymond James & Associates first reported a position in AMGN in Q2 2013 and has held it in 46 quarters since. The position peaked at $443M in Q3 2020. 2,823 funds tracked by Wall St. Rank hold AMGN as of Q3 2024.

  • Raymond James & Associates held 989,504 shares of Amgen worth $319M as of Q3 2024.
  • Raymond James & Associates sold 75,501 Amgen shares in Q3 2024, an estimated $24.7M.
  • Amgen made up 0.19% of Raymond James & Associates's portfolio in Q3 2024, its #95 holding.
  • Raymond James & Associates first reported a position in Amgen in Q2 2013 and has held it in 46 quarters since.
  • Raymond James & Associates's Amgen position peaked at $443M in Q3 2020.
  • 2,823 funds tracked by Wall St. Rank held Amgen as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.